Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;17(6):690-691.
doi: 10.1016/S1470-2045(16)30100-0. Epub 2016 May 10.

Venetoclax: a new weapon to treat high-risk CLL

Affiliations
Comment

Venetoclax: a new weapon to treat high-risk CLL

Davide Rossi. Lancet Oncol. 2016 Jun.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

  • Is venetoclax a new wonder drug in CLL?
    Fegan C, Pepper C. Fegan C, et al. Br J Haematol. 2019 May;185(4):643-646. doi: 10.1111/bjh.15836. Epub 2019 Mar 11. Br J Haematol. 2019. PMID: 30859555 No abstract available.
  • Venetoclax for the treatment of chronic lymphocytic leukemia.
    Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F. Gentile M, et al. Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Expert Opin Investig Drugs. 2017. PMID: 28972395 Review.
  • Venetoclax Yields Strong Responses in CLL.
    [No authors listed] [No authors listed] Cancer Discov. 2016 Feb;6(2):113-4. doi: 10.1158/2159-8290.CD-NB2015-180. Epub 2015 Dec 23. Cancer Discov. 2016. PMID: 26701089
  • Venetoclax-rituximab holds substantial promise in CLL.
    Killock D. Killock D. Nat Rev Clin Oncol. 2018 Jun;15(6):344-345. doi: 10.1038/s41571-018-0017-z. Nat Rev Clin Oncol. 2018. PMID: 29651129 No abstract available.
  • Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S. Del Poeta G, et al. Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.

Cited by

LinkOut - more resources